Cord Blood Cells in Patients With Acute SCI

Inclusion Criteria: * Both males and females, 18 to 75 years old * Contusion spinal cord injury (SCI) at cervical, thoracic or upper lumbar (cone level) levels * admission by 7 days post-SCI * spinal cord contusion confirmed using MRI (T1- and T2-weighted images, STIR) * ASIA A/B neurological deficit * identical level of neurological deficit at admission and at the moment of patient inclusion * primary decompressive and stabilizing surgery performed within 5 days post-SCI and prior to the first cell sample infused * patient is ready to participate and fulfill the requirements of the study protocol * informed consent signed by the patient or his legal representative Exclusion Criteria: * motor function preserved in lower limbs at admission (LEMS \> 0 points) corresponding to ASIA C, D or E deficit level * any spinal cord injury different from contusion (tear, defibering, concussion, SCIWORA, SCIWONA) confirmed using MRI * severe combined trauma (ISS \> 35 points) * inability to perform primary decompressive and stabilizing surgery within 5 days post-SCI and prior to the first cell sample infused * persistent systolic arterial pressure (AP) \> 185 mmHg or diastolic AP \> 105 mmHg or need of aggressive AP lowering using systemic antihypertensive medication at the moment of patient inclusion * acute myocardial infarction * blood glucose level \< 3.5 Mmol/L or \>21 Mmol/L or ineffective antidiabetic therapy for 24 hours * acute or deterioration of chronic diseases of central nervous system (CNS) (e.g. stroke, non-traumatic subarachnoid hemorrhages and others at the discretion of investigator) * hypotension or cardiovascular shock AND systolic AP \< 90 mmHg OR need for intensive systemic inotropic therapy at the moment of patient inclusion * objective need for artificial ling ventilation (ALV) at admission or prior to the stage I surgery * acute kidney failure or deterioration of chronic kidney failure (creatinin level \> 250 mumol/L or carbamide level \> 25 Mmol/L) * liver failure (general bilirubin level \> 25 mumol/L, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels \> 4 times exceeding upper reference limit) * other significant disorders of vital functions * acute of deterioration of chronic diseases of internal organs preventing from cell samples infusion * autoimmune diseases (active or anamnestic) preventing from cell samples infusion * allergic reactions of any type for any component of HUCBC samples * pregnancy or lactation * significant surgeries or severe traumas within 3 months prior to patient inclusion * acute or chronic infection diseases (tuberculosis, lues, HIV, hepatitis B, hepatitis C etc.) * moderate or severe hematological and/or oncohematological diseases preventing from the cell samples infusion * any malignant tumors (both operated and not operated) or benign tumors (not operated or not totally removed) at the moment of patient inclusion * neurological and/or psychiatric diseases preventing patient from complete understanding of study protocol or fulfillment of the study protocol requirements * other reasons preventing patient from complete understanding of study protocol or fulfillment of the study protocol requirements * patient's participation in any other clinical trials or studies within 6 months prior to inclusion * immunosuppressive therapy obtained by the patient for any reason at admission * allergic reaction for full blood or blood component transfusion in the past * need for extracorporal detoxication methods application (hemodialysis, plasmapheresis, sorption etc.) * bone marrow or internal organs (both donor and relative) transplantation in the past * patient's participation in any studies applying regenerative technologies (grow factors, cytokines, cell therapy, gene therapy etc.) within 1 year prior to inclusion * patient's rejection to sign the informed consent * any other reasons preventing patient's inclusion according to the investigator's opinion